Dorsey Wright & Associates Boosted Its Nice Sys LTD Sponsored Adr (NICE) Holding; Esperion Therapeutics Has 0.88 Sentiment

July 17, 2017 - By Marie Mckinney

Dorsey Wright & Associates increased Nice Sys Ltd Sponsored Adr (NICE) stake by 120.49% reported in 2016Q4 SEC filing. Dorsey Wright & Associates acquired 9,838 shares as Nice Sys Ltd Sponsored Adr (NICE)’s stock rose 7.66%. The Dorsey Wright & Associates holds 18,003 shares with $1.24 million value, up from 8,165 last quarter. Nice Sys Ltd Sponsored Adr now has $4.80 billion valuation. It closed at $78.65 lastly. It is down 16.65% since July 17, 2016 and is uptrending. It has underperformed by 0.05% the S&P500.

Esperion Therapeutics, Inc. is a lipid management company. The company has market cap of $1.13 billion. The Firm is a late-stage pharmaceutical firm focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . It currently has negative earnings. With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Among 9 analysts covering NICE Systems (NASDAQ:NICE), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. NICE Systems had 13 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Overweight” rating by JP Morgan given on Wednesday, June 29. The stock has “Buy” rating by Chardan Capital Markets on Wednesday, January 11. The firm has “In-Line” rating by Imperial Capital given on Friday, January 13. The firm has “Sector Perform” rating given on Friday, February 12 by RBC Capital Markets. As per Wednesday, June 22, the company rating was initiated by Chardan Capital Markets. JMP Securities upgraded it to “Market Outperform” rating and $78 target in Thursday, May 26 report. Zacks upgraded the stock to “Hold” rating in Wednesday, August 5 report. As per Friday, May 27, the company rating was downgraded by UBS. FBR Capital maintained the shares of NICE in report on Thursday, July 30 with “Outperform” rating. UBS upgraded Nice Ltd (ADR) (NASDAQ:NICE) on Wednesday, August 26 to “Neutral” rating.

About 150 shares traded. Esperion Therapeutics Inc (ESPR) has risen 133.75% since July 17, 2016 and is uptrending. It has outperformed by 117.05% the S&P500.

Ratings analysis reveals 0 of Esperion Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Esperion Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ESPR was included in 2 notes of analysts from November 14, 2016. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Sector Perform” rating by RBC Capital Markets on Thursday, February 23. The rating was downgraded by Citigroup to “Neutral” on Monday, November 14.

Analysts await Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings on August, 3. They expect $-1.67 earnings per share, down 169.35% or $1.05 from last year’s $-0.62 per share. After $-1.80 actual earnings per share reported by Esperion Therapeutics Inc for the previous quarter, Wall Street now forecasts -7.22% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: